INCB123667
Small molecule
Evidence outlook · registrational
Ovarian Cancer: registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2027-10-12.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
MAESTRA 3 NCT07797283 · Ovarian Cancer Registry: NCT07797283 | 3 | Progression-Free Survival (PFS) by BICR (Up to approximately 5 years) 2032-05-01 | In progress: results expected 1 May 2032 | not yet graded | link ↗ |
View 1 more trial
MAESTRA 2 NCT07214779 · Ovarian Cancer Registry: NCT07214779 | 3 | Progression-Free Survival (PFS) by BICR (Up to 2 years); Overall Survival (OS) (Up to 2 years) 2027-10-12 | In progress: results expected 15 Nov 2028 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 2 (1)
What this study did
Phase 1 (4)
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other CDK2 drugs
AVZO-021, ECI830, GVV858, Tegtociclib, BG-68501. Compare all 6 CDK2 drugs
5 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Ovarian Cancer: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| INCB123667: this drug | Phase 3 | Small molecule | CDK2 | not yet graded | No reviewed efficacy summary in this indication | |
| Avutometinib / Defactinib (Avmapki Fakzynja Co-Pack) | Approved | Small molecule | MEK1/2 and RAF (CRAF, BRAF), FAK | not yet graded | No reviewed efficacy summary in this indication | |
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | not yet graded | No reviewed efficacy summary in this indication | |
| Gemcitabine | ApprovedUS marketing discontinued | Small molecule | ribonucleotide reductase / DNA polymerase (dCTP competition) | not yet graded | No reviewed efficacy summary in this indication | |
| Jobevne (bevacizumab-Nwgd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Mirvetuximab Soravtansine (Elahere) | Approved | Antibody–drug conjugate | — | not yet graded | No reviewed efficacy summary in this indication | |
| Niraparib | Approved | Small molecule | PARP1/2 | Reliable signal | NCT02655016: Progression Free Survival (Up to 34 months): Placebo 8.2 Months (95% CI 7.3 to 8.5) | Niraparib 13.8 Months (95% CI 11.5 to 14.9) | |
| Olaparib | Approved | Small molecule | PARP | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Reliable signal | No reviewed efficacy summary in this indication | |
| Relacorilant (Lifyorli) | Approved | Small molecule | Glucocorticoid receptor | Partial signal | No reviewed efficacy summary in this indication | |
| Rucaparib | Approved | Small molecule | PARP (poly ADP-ribose polymerase) enzymes, PARP1/2 | Reliable signal | Featured results are non-efficacy only in this race | |
| Vegzelma (bevacizumab-Adcd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Durvalumab | Phase 3 | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| GSK 5733584 | Phase 3 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| Izalontamab Brengitecan | Phase 3 | Antibody–drug conjugate | EGFR + HER3 | not yet graded | No reviewed efficacy summary in this indication | |
| Olvimulogene Nanivacirepvec | Phase 3 | Oncolytic virus | No discrete molecular target | not yet graded | No reviewed efficacy summary in this indication | |
| Raludotatug Deruxtecan | Phase 3 | Antibody–drug conjugate | CDH6 (Cadherin-6) | not yet graded | No reviewed efficacy summary in this indication | |
| Rinatabart Sesutecan (Rina-S) | Phase 3 | Antibody–drug conjugate | Folate receptor alpha (FRα) | not yet graded | No reviewed efficacy summary in this indication | |
| Sacituzumab Tirumotecan | Phase 3 | Antibody–drug conjugate | TROP2 | not yet graded | No reviewed efficacy summary in this indication | |
| Sofetabart Mipitecan | Phase 3 | Antibody–drug conjugate | Folate receptor alpha (FRα) | not yet graded | No reviewed efficacy summary in this indication | |
| Torvutatug Samrotecan | Phase 3 | Antibody–drug conjugate | Folate receptor alpha (FRα) | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Brengitecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Rezetecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Birinapant | Phase 2 | — | IAP (inhibitor of apoptosis) proteins | not yet graded | No reviewed efficacy summary in this indication | |
| Ixotatug Vedotin | Phase 2 | Antibody–drug conjugate | Claudin 6 (CLDN6) | not yet graded | No reviewed efficacy summary in this indication | |
| Stenoparib | Phase 2 | Small molecule | PARP1/2, Tankyrase 1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| AVZO-021 | Phase 1/2(overall) | Small molecule | CDK2 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| COM701 | Phase 1/2 | Monoclonal antibody | PVRIG (CD112R) | not yet graded | No reviewed efficacy summary in this indication | |
| ECI830 | Phase 1/2(overall) | Small molecule | CDK2 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| GVV858 | Phase 1/2(overall) | — | CDK2 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| REGN5668 | Phase 1/2 | Multispecific antibody | MUC16 x CD28 | not yet graded | No reviewed efficacy summary in this indication | |
| Rezatapopt | Phase 1/2 | Small molecule | p53 reactivator | not yet graded | No reviewed efficacy summary in this indication | |
| Tegtociclib | Phase 1/2(overall) | Small molecule | CDK2 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| TUB-040 | Phase 1/2 | Antibody–drug conjugate | NaPi2b (sodium-dependent phosphate transporter, SLC34A2) | not yet graded | No reviewed efficacy summary in this indication | |
| Ubamatamab | Phase 1/2 | Monoclonal antibody | MUC16 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| 27T51 | Phase 1 | Cell therapy | MUC16 | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-901 | Phase 1 | Undisclosed | Folate receptor alpha (FRα) | not yet graded | No reviewed efficacy summary in this indication | |
| APG-2449 | Phase 1 | Small molecule | FAK / ALK / ROS1 | not yet graded | No reviewed efficacy summary in this indication | |
| BG-68501 | Phase 1(overall) | Small molecule | CDK2 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| CRX100 | Phase 1 | Cell therapy | Cell-based oncolytic virus immunotherapy | not yet graded | No reviewed efficacy summary in this indication | |
| IDE-161 | Phase 1 | Small molecule | PARG | not yet graded | No reviewed efficacy summary in this indication | |
| XmAb541 | Phase 1 | Multispecific antibody | Claudin 6 (CLDN6) x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Luveltamab Tazevibulin | Discontinued | Antibody–drug conjugate | Folate receptor alpha (FRα) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow INCB123667 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.